Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ALE.C04 |
| Trade Name | |
| Synonyms | ALE C04|ALE-C04|ALEC04 |
| Drug Descriptions |
ALE.C04 is a monoclonal antibody that targets CLDN1, potentially leading to enhanced T-lymphocyte infiltration and inhibition of tumor growth (Cancer Res (2023) 83 (8_Supplement): LB284). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C201755 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ALE.C04 | ALE.C04 | 0 | 1 |
| ALE.C04 + Pembrolizumab | ALE.C04 Pembrolizumab | 0 | 1 |